Thanks Maui and Bornet for sharing your thoughts.
Post# of 30066
(Total Views: 449)
Posted On: 07/19/2019 10:45:08 PM
Thanks Maui and Bornet for sharing your thoughts. Like you and all the longtime shareholders on this board, I'm beyond ready to get some news that truly moves AMBS share price towards a more reasonable valuation.
I follow the biopharma industry on a weekly if not daily basis to stay current on news related to clinical studies, deals, regulatory changes, etc. And I'm sure this isn't news to you, but there is NOT a shortage of capital when it comes to this sector. Investors are giving millions of dollars to companies with far less researched and promising assets. In fact, some of those assets are still in the pre-clinical phase!
I understand that our financial challenges got us off track for a while, but those issues have been addressed. As excited as I am about the near-term Todos catalyst (and possible Coeptis developments), I would be more excited if I saw signs of greater urgency around getting a development partner for MANF.
With the potential MANF has shown in the retinal disease space alone, the market has recently shown there are deep pocket companies out there willing to pay for access to these assets. A few retinal disease examples just in 2019 include Roche/Spark, Biogen/Nightstar, and Janssen/Meiragtx.
Bottom line for me, many of AMBS's investors have been some of the most patient any management team could ask for and it's time to reward that patience. Thanks again for sharing. I appreciate all the contributions everyone makes on this board.
I follow the biopharma industry on a weekly if not daily basis to stay current on news related to clinical studies, deals, regulatory changes, etc. And I'm sure this isn't news to you, but there is NOT a shortage of capital when it comes to this sector. Investors are giving millions of dollars to companies with far less researched and promising assets. In fact, some of those assets are still in the pre-clinical phase!
I understand that our financial challenges got us off track for a while, but those issues have been addressed. As excited as I am about the near-term Todos catalyst (and possible Coeptis developments), I would be more excited if I saw signs of greater urgency around getting a development partner for MANF.
With the potential MANF has shown in the retinal disease space alone, the market has recently shown there are deep pocket companies out there willing to pay for access to these assets. A few retinal disease examples just in 2019 include Roche/Spark, Biogen/Nightstar, and Janssen/Meiragtx.
Bottom line for me, many of AMBS's investors have been some of the most patient any management team could ask for and it's time to reward that patience. Thanks again for sharing. I appreciate all the contributions everyone makes on this board.
(2)
(0)